---
title: "MASH / MASLD"
canonical: "https://www.pharmalegacy.com/indications/hepatic-renal-disease-models/nafld-nash/"
lastmod: "2026-05-25T18:56:45+00:00"
generator: "llm-mirrors/1.0.19"
---

Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), is distinguished from other hepatic disorders by hepatocyte ballooning and degeneration as well as lobular inflammation which can eventually deteriorate into liver fibrosis. If it remains untreated, MASH can develop into cirrhosis, and in some instances, hepatocellular carcinoma (HCC).
The biggest challenge in MASH preclinical studies is finding an animal model that provides your pipeline with enough similarity to the human disease state and translatability into clinical applications. Our MASH models at PharmaLegacy offer you with a well-rounded choice that ultimately depends on the facet of MASH your study is tackling. Not sure which model suits you best? Contact PharmaLegacy and our experts will give you the answers you need.